Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 2) (SSB 11-02)
Composite of the following events through one month: initiation of the index endovascular procedure following the debranching procedure, device technical success for the index endovascular procedure and absence of the following Core Lab and adverse events: aortic rupture, lesion related mortality, disabling stroke, permanent paraplegia, permanent paraparesis, new onset renal failure requiring permanent dialysis, additional unanticipated post-procedural surgical or interventional procedure related to the device, procedure, or withdrawal of the delivery system.
Age:18 Years and older (Adult, Older Adult)
Disease condition: No healthy volunteers
1.Presence of thoracic aortic pathology deemed to warrant surgical repair which requires proximal graft placement in Zone 0-2.
2.Age ≥18 years at time of informed consent signature
3.Subject is capable of complying with protocol requirements, including follow-up
4.Informed Consent Form (ICF) is signed by Subject or legal representative
5.Must have appropriate proximal aortic landing zone.
6.Must have appropriate target branch vessel landing zone
7.For patients with aneurysm/isolated lesion, must have appropriate distal aortic landing zone.Exclusion Criteria:
1.Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair
2.Previous endovascular repair of the ascending aorta
3.Previous endovascular repair of the DTA with a non-Gore device
4.Surgery within 30 days prior to enrollment, with the exception of surgery for Ascending Aortic Dissection and/or placement of vascular conduit for access
6.Life expectancy <2 years
<!--2--> 7.Myocardial infarction within 6 weeks prior to treatment
8.Stroke within 6 weeks prior to treatment, stroke defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular origin.
9.Patient has a systemic infection and may be at increased risk of endovascular graft infection
10.Pregnant female at time of informed consent signature
11.Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome
12.Participation in another drug or medical device study within one year of study enrollment
13.Known history of drug abuse within one year of treatment
14.Presence of protruding and/or irregular thrombus and/or atheroma in the aortic arch or ascending aorta
15.Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access
16.Planned coverage of celiac artery
17.Patient has known sensitivities or allergies to the device materials
18.Patient has known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
19.Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
20.Patient with a history of a hypercoagulability disorder and/or hypercoagulability state
21.Diameter taper outside of the device sizing range between proximal and distal landing zones of aorta and the inability to use additional devices of different diameters to compensate for the taper
23.Persistent refractory shock (systolic blood pressure <90 mm Hg)
<!--90--> 24.Patient has body habitus or other medical condition which prevents adequate visualization of the aorta
25.Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 or currently requiring dialysis
Additional eligibility criteria and study procedure details can be explained by the study team. Please call or email:
Can be done from home
KeywordsAortic Disease, Aneurysm Aortic
Principal InvestigatorMichael, Himanshu Drake, Patel, MD, MD
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.